Anticancer Research

Anticancer Research

抗癌研究

  • 4区 中科院分区
  • Q4 JCR分区

期刊简介

《Anticancer Research》是由International Institute of Anticancer Research出版社于1981年创办的英文国际期刊(ISSN: 0250-7005,E-ISSN: 1791-7530),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为医学-肿瘤学。作为SCIE收录期刊(JCR分区 Q4,中科院 4区),本刊采用OA未开放获取模式(OA占比0.0023...%),以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比92.46%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在637篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Anticancer Research审稿周期约为 约2月 。该刊近年未被列入国际预警名单,年发文量约637篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 637 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ONCOLOGY 肿瘤学
4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ONCOLOGY 肿瘤学
4区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q4 253 / 322

21.6%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 232 / 322

28.11%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:3.7 SJR:0.562 SNIP:0.558
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q3 227 / 404

43%

大类:Medicine 小类:Cancer Research Q3 164 / 230

28%

期刊发文

  • Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage

    Author: Xiao, H. A. I. N. I. A. O.; Wu, Z. H. I. G. A. N. G.; Wang, Q. I. N. Q. U. A. N.; Zhou, C. H. A. O. F. E. N. G.; Lu, F. E. N. G.; Xiao, Y. U. N. B. E., I

    Journal: ANTICANCER RESEARCH. 2023; Vol. 43, Issue 1, pp. 389-403. DOI: 10.21873/anticanres.16174

  • Association of Matrix Metalloproteinase-7 Genotypes With Prostate Cancer Risk

    Author: Liao, Cheng-hsi; Chang, Wen-shin; Hsu, Wei-lin; Hu, Pei-shin; Wu, Hsi-chin; Hsu, Shih-wei; Wang, Bo-ren; Yueh, Te-cheng; Chen, Chao-hsuan; Hsia, Te-chun; Huang, Wen-chin; Bau, Da-tian; Tsai, Chia-wen

    Journal: ANTICANCER RESEARCH. 2023; Vol. 43, Issue 1, pp. 381-387. DOI: 10.21873/anticanres.16173

  • Association of Matrix Metalloproteinase-2 Genotypes With Prostate Cancer Risk

    Author: LI, Po-han; Liao, Cheng-hsi; Huang, Wen-chin; Chang, Wen-shin; Wu, Hsi-chin; Hsu, Shih-wei; Chen, Kai-yuan; Wang, Zhi-hong; Hsia, Te-chun; Bau, Da-tian; Tsai, Chia-wen

    Journal: ANTICANCER RESEARCH. 2023; Vol. 43, Issue 1, pp. 343-349. DOI: 10.21873/anticanres.16169

  • Clinical Value of Magnetic Resonance Imaging Combined With Serum Prostate-specific Antigen, Epithelial Cadherin and Early Prostate Cancer Antigen 2 In Diagnosis of Prostate Cancer

    Author: Li, Kun; Luan, Qingxia; Zheng, Junze; Li, Ruidong; Li, Linkun; Sun, Yequan; Liu, Donghui

    Journal: ANTICANCER RESEARCH. 2023; Vol. 43, Issue 1, pp. 441-447. DOI: 10.21873/anticanres.16180

  • CTHRC1 Is Associated With Immune Escape and Poor Prognosis in Gastric Cancer

    Author: Hu, Yangzhi; Huang, Lijuan; Zhao, Kailai; Li, Yuan; Givens, Nathan T.; Heslin, Aidan J.; Deng, Zuliang; Cao, Liequan; Fang, Yujiang

    Journal: ANTICANCER RESEARCH. 2023; Vol. 43, Issue 1, pp. 115-126. DOI: 10.21873/anticanres.16140

  • Fluoxetine Inhibits STAT3-mediated Survival and Invasion of Osteosarcoma Cells

    Author: Chen, Wei-Ting; Tsai, Yuan-Hsin; Tan, Peggy; Hsu, Fei-Ting; Wang, Hui-Min David; Lin, Wei-Chin; Lin, Feng-Huei; Wu, Ching-Te

    Journal: ANTICANCER RESEARCH. 2023; Vol. 43, Issue 3, pp. 1193-1199. DOI: 10.21873/anticanres.16265

  • Etomidate Suppresses Invasion and Migration of Human A549 Lung Adenocarcinoma Cells.

    Author: Chu CN1,2, Wu KC3,4, Chung WS5, Zheng LC6, Juan TK6, Hsiao YT6, Peng SF6, Yang JL6, Ma YS7,8, Wu RS9,10, Chung JG11,12.

    Journal: Anticancer Res. 2019 Jan;39(1):215-223. doi: 10.21873/anticanres.13100.

  • Cell-penetrating Peptide-coated Liposomes for Drug Delivery Across the Blood-Brain Barrier.

    Author: Yuan BO1, Zhao Y2, Dong S2, Sun Y2, Hao F2, Xie J2, Teng L2, Lee RJ3,4, Fu Y5, Bi YE3,6.

    Journal: Anticancer Res. 2019 Jan;39(1):237-243. doi: 10.21873/anticanres.13103.